EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Understanding Impact of Anti‐Obesity Medications on Skeletal Muscle Mass Change Is Confounded by Measurement Methods

Arden McMath iD, Dympna Gallagher

Obesity Reviews · 2026-04 · 27 (4)

DOI: 10.1111/obr.70041 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Obesity Reviews, online erschienen am 24.11.2025. Verfasst von Arden McMath und 1 weiteren Autor:innen. Beteiligte Einrichtung: New York Nutrition Obesity Research Center, Columbia University, New York City, USA. Hauptthemen laut MEDLINE: Muscle, Skeletal, Anti-Obesity Agents, Obesity, Weight Loss. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIDDK NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti‐obesity medications promote greater degrees of weight loss than lifestyle interventions alone. There is an important need to understand whether loss of skeletal muscle during pharmacologically induced weight loss is clinically significant due to its essential role in health and disease. Most randomized, placebo‐controlled studies addressing this question report on fat‐free or lean mass estimated from dual‐energy x‐ray absorptiometry or bioelectrical impedance without defining the composition of these components. Fat‐free, lean, and skeletal muscle mass are not synonymous terms, and studies frequently fail to define lean mass, which may or may not include bone. Lack of standard preparatory procedures prior to measurement, differences in medications, doses, or intervention lengths, and inclusion of varied lifestyle modifications prevent reaching a consensus regarding the impact on skeletal muscle of pharmacologically induced weight loss. There is a critical need for greater precision and depth of understanding when selecting a measurement method and describing body compartments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscle, SkeletalAnti-Obesity AgentsObesityWeight LossBody CompositionHumansAbsorptiometry, PhotonElectric Impedance

Stichwörter der Autor:innen

body compositionglucagon‐like peptide‐1 receptor agonistsobesityoverweightanti‐obesity medicationsskeletal muscle mass

Substanzen

Anti-Obesity Agents

Autor:innen und Institutionen

  • New York Nutrition Obesity Research Center, Columbia University, New York City, USA.
  • Division of Endocrinology, Department of Medicine, Columbia University Irving Medical Center, New York City, USA.
  • Institute of Human Nutrition, Columbia University, New York City, USA.

ORCID-Profile: Arden McMath

Förderung

  • NIH HHS
  • NIDDK NIH HHS
  • National Institutes of Health

Zitieren

APA

McMath, A., & Gallagher, D. (2026). Understanding Impact of Anti‐Obesity Medications on Skeletal Muscle Mass Change Is Confounded by Measurement Methods. Obesity Reviews, 27(4). https://doi.org/10.1111/obr.70041

Vancouver

McMath A, Gallagher D. Understanding Impact of Anti‐Obesity Medications on Skeletal Muscle Mass Change Is Confounded by Measurement Methods. Obesity Reviews. 2026;27(4). doi:10.1111/obr.70041

BibTeX
@article{McMath2026,
  author = {McMath, Arden and Gallagher, Dympna},
  title = {Understanding Impact of Anti‐Obesity Medications on Skeletal Muscle Mass Change Is Confounded by Measurement Methods},
  journal = {Obesity Reviews},
  year = {2026},
  volume = {27},
  number = {4},
  doi = {10.1111/obr.70041}
}
Kostenlos starten →